Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways [Original Articles]

Conclusions— This study demonstrates that cardiac KCNE2 expression is decreased and contributes to the development of hypertrophy via activation of calcineurin–NFAT and mitogen-activated protein kinase pathways. Targeting KCNE2 is a potential therapeutic strategy for the treatment of hypertrophy.

http://circheartfailure.ahajournals.org/cgi/content/short/10/6/e003960?rss=1

Source: Circulation: Heart Failure - June 13, 2017 Category: Cardiology Authors: Liu, W., Deng, J., Ding, W., Wang, G., Shen, Y., Zheng, J., Zhang, X., Luo, Y., Lv, C., Wang, Y., Chen, L., Yan, D., Boudreau, R. L., Song, L.-S., Liu, J. Tags: Cardiomyopathy, Heart Failure, Hypertrophy Original Articles Source Type: research